The US government will begin a coordinated wind-down of 22 mRNA vaccine-development projects, representing funding of $500 million. mRNA technology came into prominence as vaccines against COVID-19. What projects are affected?
The CDMO/CMO Report: What’s Trending in Drug Products?
What dosage forms are leading the way among new drug approvals thus far in 2025? DCAT Value Chain Insights examines the key trends and latest developments in drug delivery and drug-product development and manufacturing.
The US and the EU came to terms on new trade deal, which includes a single, all-inclusive US tariff ceiling of 15% for EU goods. How do pharmaceuticals factor into…
Bio/Pharma Industry Radar: Top Mergers & Acquisitions Thus Far in 2025
With all eyes on the tariff situation between the EU-US, what about the EU chemicals industry as a whole? The European Commission has released an action plan to revitalize the industry.
FDA Begins Pilot for Speeding Drug Reviews with A Priority for Reshoring Mfg
FDA is starting a new pilot program to reduce review times from 10-12 months to 1-2 months for certain drugs, with one priority given to drugs that reshore/onshore manufacturing to the US.
The Next Round in the EU–US Tariff Battle: What’s the Impact on API Supply?
Facing a potential US tariff of 30% coming due on August 1, European Union leaders are mapping out a trade strategy. What’s the impact on pharmaceutical supply chains?
The Top 25 Supply Chain Organizations: Where Does Pharma Rank?
The White House extended the deadline to impose reciprocal tariffs on most countries until August 1st. What is the impact on manufacturing & supply lines, and what may be next?
With budgetary and staffing cuts at FDA, have approvals of new drugs slowed? DCAT Value Chain Insights looks at the numbers and key trends in new drug approvals thus far in 2025.
